• 091914_hepatitis_sm

    Gilead Sciences Comes to Capitol Hill

    BY Allie Freedman
    Hepatitis C briefing pushes for reduced treatment cost

    U.S. biopharmaceutical company Gilead Sciences briefed members of Congress last week about the impact and developments of new Hepatitis C medications. Led by Gilead Vice President Coy Stout, the event showcased physicians’ and patients’ perspectives on the liver disease, bringing a panel that included Dr. Natarajan Ravendhran, chief of gastroenterology and liver disease...CONTINUE »